Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1α, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer

Cancer Research

Volumn 69, Issue 20, 2009, Pages 7905-7910

  Lei, Xu ^a   Duda, Dan G ^a   Di Tomaso, Emmanuelle ^a   Ancukiewicz, Marek ^a   Chung, Daniel C ^a   Lauwers, Gregory Y ^a   Samuel, Rekha ^a   Shellito, Paul ^a   Czito, Brian G ^b   Lin, Pei Chun ^a   Poleski, Martin ^b   Bentley, Rex ^b   Clark, Jeffrey W ^a   Willett, Christopher G ^b   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHEMOKINE RECEPTOR CXCR4; GRANULOCYTE CHEMOTACTIC PROTEIN 2; NEUROPILIN 1; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN ANTIBODY;

ARTICLE; CANCER CELL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HUMAN; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECTUM CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BIOPSY; TUMOR VOLUME; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHEMOKINE CXCL12; CHEMOKINE CXCL6; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEUROPILIN-1; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, CXCR4; RECTAL NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70350225520     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2099     Document Type: Article

References (20)

1. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327-338
2. Wolmark N, Yothers G, O'Connell MG, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009;27:(suppl; abstr LBA4).
3. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
4. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83-95. (Pubitemid 46075199)
5. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009;27:3027-3035
6. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997;57:3924-3928 (Pubitemid 27427677)
7. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
8. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009;27:3020-3026
9. Guleng B, Tateishi K, Ohta M, et al. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res 2005;65:5864-5871 (Pubitemid 40911192)
10. Kollmar O, Rupertus K, Scheuer C, et al. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007;9:862-870 (Pubitemid 47623426)
11. Gijsbers K, Gouwy M, Struyf S, et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in gastrointestinal tumors. Exp Cell Res 2005;303:331-342 (Pubitemid 40126267)
12. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
13. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005;23:8136-8139 (Pubitemid 46657433)
14. Gustafsson C, Mjosberg J, Matussek A, et al. Gene expression profiling of human decidual macrophages: evidence for immunosuppressive phenotype. PLoS ONE 2008;3:e2078. (Pubitemid 352025020)
15. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78
16. Brand S, Dambacher J, Beigel F, et al. CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. Exp Cell Res 2005;310:117-130 (Pubitemid 41393693)
17. Grothey A. Future directions in vascular endothelial growth factor-targeted therapy for metastatic colorectal cancer. Semin Oncol 2006;33:S41-9. (Pubitemid 44634010)
18. Waldner MJ, Neurath MF. Cytokines in colitis associated cancer: potential drug targets? Inflamm Allergy Drug Targets 2008;7:187-194
19. Parikh AA, Fan F, Liu WB, et al. Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis. Am J Pathol 2004;164:2139-2151 (Pubitemid 38669361)
20. Pan Q, Chanthery Y, Wu Y, et al. Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. J Biol Chem 2007;282:24049-24056 (Pubitemid 47328044)